Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial

Rational, Trial Design, and Results of the Rational, Trial Design, and Results of the ADAGIO Delayed Start TrialADAGIO Delayed Start Trial

C. Warren Olanow, MD, FRCPCC. Warren Olanow, MD, FRCPCHenry P. and Georgette Goldschmidt ProfessorHenry P. and Georgette Goldschmidt ProfessorChairman Emeritus, Department of NeurologyChairman Emeritus, Department of Neurology

Professor, Department of NeuroscienceProfessor, Department of NeuroscienceDirector, Robert and John M. Bendheim Parkinson's Disease CenterDirector, Robert and John M. Bendheim Parkinson's Disease Center

Mount Sinai School of MedicineMount Sinai School of MedicineNew York, New YorkNew York, New York

Mechanisms ● Mortality ● TherapeuticsMechanisms ● Mortality ● Therapeutics

Schematic Illustration of the Three Schematic Illustration of the Three Primary End Points of the StudyPrimary End Points of the Study

Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.

Randomization and Treatment Randomization and Treatment of the Study Subjectsof the Study Subjects

Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.

Baseline CharacteristicsBaseline Characteristics

Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.

Results for Primary and Results for Primary and Secondary CharacteristicsSecondary Characteristics

Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.

Changes in Scores on the Unified Changes in Scores on the Unified Parkinson’s Disease Rating ScaleParkinson’s Disease Rating Scale

Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.

Adverse EventsAdverse EventsAccording to Treatment GroupAccording to Treatment Group

Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.

Adverse EventsAdverse EventsAccording to Treatment Group (cont)According to Treatment Group (cont)

Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.

Adverse EventsAdverse EventsAccording to Treatment Group (cont)According to Treatment Group (cont)

Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.